FreeCME

Rationale and Evidence for Individualized Treatment Decisions in gMG

CME: 1.0

September 9, 2022
/ Print / Reprints /
| Share More
/ Text Size+

Target Audience

The intended audience for this activity are neurology, neuromuscular, neuroimmunology, and neuro-ophthalmology specialists, along with advanced practice neurology practitioners, such as neurology NPs, neurology PAs, and clinical pharmacists.

Program Overview

The treatment paradigm for generalized myasthenia gravis (gMG) is changing rapidly with the availability of new antibody tests and targeted treatment options. The treatment landscape for gMG is shifting from reliance on nonspecific immunosuppressants to personalized targeted approaches that address the underlying pathophysiology and achieve disease remission. More than ever, clinicians must engage their patients with gMG in shared decision-making to ensure treatment selection aligns with patient characteristics, preferences, and goals.

The 60-minute CME-certified activity, “Rationale and Evidence for Individualized Treatment Decisions in gMG,” will review recently approved and emerging treatment options that have shown a more rapid onset of effect and improved disease control than traditional treatments. Expert panelists will review clinically important gMG outcomes measures and compare the safety and efficacy profiles of both current and emerging treatments for patients with gMG.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the burden of gMG disease and its treatment with traditional options
  • Summarize the targeted mechanisms of action, efficacy, safety, and place in therapy of new and emerging treatments for gMG with a focus on FcRn-receptor antagonists
  • Describe how accounting for patient characteristics (autoantibody status, MG presentation), preferences, desire to maintain autonomy, quality of life, and treatment goals can impact treatment selection

Post a comment to this article